2023
Change in Smoking Behavior and Outcome After Ischemic Stroke: Post-Hoc Analysis of the SPS3 Trial
Anadani M, Turan T, Yaghi S, Spiotta A, Gory B, Sharma R, Sheth K, de Havenon A. Change in Smoking Behavior and Outcome After Ischemic Stroke: Post-Hoc Analysis of the SPS3 Trial. Stroke 2023, 54: 921-927. PMID: 36876480, PMCID: PMC10050138, DOI: 10.1161/strokeaha.121.038202.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsAcute ischemic strokeIschemic strokeCardiovascular eventsPersistent smokersPersistent smokingSPS3 trialSmoking statusMyocardial infarctionMajor adverse cardiovascular events outcomesCardiovascular event outcomesMajor cardiovascular outcomesSubsequent cardiovascular eventsHistory of hypertensionRisk of strokeEnd of studyPost Hoc AnalysisPrior smokersRandomization armCardiovascular outcomesFormer smokersMonth 3Primary outcomeTotal cohort
2022
Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial
Lang A, de Havenon A, Mac Grory B, Henninger N, Shu L, Furie K, Easton J, Kim A, Johnston S, Yaghi S. Subsequent ischemic stroke and tobacco smoking: A secondary analysis of the POINT trial. European Stroke Journal 2022, 8: 328-333. PMID: 37021190, PMCID: PMC10069178, DOI: 10.1177/23969873221148224.Peer-Reviewed Original ResearchConceptsSubsequent ischemic strokeEffect of clopidogrelSubsequent stroke riskIschemic strokeMajor hemorrhagePoint trialStroke riskSmoking statusMinor Ischemic Stroke (POINT) trialSubgroup interaction analysesMultivariable Cox regressionMinor ischemic strokeIschemic stroke trialsEffect of smokingNon-significant trendNew TIACurrent smokersStroke trialsTobacco smokingCox regressionIndex eventSmokersSecondary analysisClopidogrelStroke